Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe [PDF]
Orphanet Journal of Rare Diseases, 2021 Background Real-world studies of the burden of severe haemophilia B in the context of recent therapeutic advances such as extended half-life (EHL) factor IX (FIX) products are limited.
Tom Burke +5 more
doaj +4 more sources
Eftrenonacog Alfa: A Review in Haemophilia B. [PDF]
Drugs, 2023 Eftrenonacog alfa (Alprolix®) is an extended half-life recombinant factor IX (rFIX)-Fc fusion protein (hereafter referred to as rFIXFc). Administered as an intravenous bolus, it is approved for prophylactic use and the treatment of bleeding in patients with haemophilia B in various countries worldwide, including those of the EU, as well as the USA.
Lamb YN, Hoy SM.
europepmc +4 more sources
Haemophilia specialist nurses’ perceptions of haemophilia B [PDF]
The Journal of Haemophilia Practice, 2021 Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes.
Chaplin Steve +9 more
doaj +2 more sources
International consensus recommendations on the management of people with haemophilia B [PDF]
Therapeutic Advances in Hematology, 2022 Haemophilia B is a rare X-linked genetic deficiency of coagulation factor IX (FIX) that, if untreated, can cause recurrent and disabling bleeding, potentially leading to severe arthropathy and/or life-threatening haemorrhage.
Daniel P. Hart +14 more
doaj +2 more sources
Haemophilia A and haemophilia B: molecular insights [PDF]
Molecular Pathology, 2002 This review focuses on selected areas that should interest both the scientist and the clinician alike: polymorphisms within the factor VIII and factor IX genes, their linkage, and their ethnic variation; a general assessment of mutations within both genes and a detailed inspection of the molecular pathology of certain mutations to illustrate the ...
D. J. Bowen
openalex +8 more sources
Perioperative management of a patient with haemophilia B and PSVT undergoing radiofrequency ablation: A case report [PDF]
Journal of International Medical Research, 2023 Haemophilia B is a rare inherited bleeding disorder in which patients have impaired coagulation. This study describes a patient with Haemophilia B and paroxysmal supraventricular tachycardia (PSVT) who underwent radio frequency catheter ablation (RFCA ...
Yu Gan, Liping Ma, Pihua Fang
doaj +2 more sources
Intracranial haemorrhage in haemophilia A and B [PDF]
British Journal of Haematology, 2007 SummaryIn countries with a good standard of health care, intracranial haemorrhage (ICH) during the neonatal period affects 3·5–4·0% of all haemophilia boys, which is considerably (40–80 times) higher than expected in the normal population. ICHs are also frequent after the neonatal period, affecting 3–10% of the haemophilia population who are mainly ...
Rolf Ljung
openalex +4 more sources
Gene therapy for haemophilia B [PDF]
Haemophilia, 2012 Summary. AAV virus mediated transfer of factor IX to humans is safe and effective at three dose levels. Two subjects treated at highest dose level developed immune mediated transaminitis which resolved on a short course of Prednisolone. Beneficial effects in terms of continuous elevation of factor IX level above base line was seen in all subjects ...
Edward G. D. Tuddenham
openalex +4 more sources
The Molecular Genetics of Haemophilia A and B [PDF]
Journal of Cell Science, 1986 G.G. Brownlee
openalex +4 more sources
Correction to: Eftrenonacog Alfa: A Review in Haemophilia B. [PDF]
Drugs, 2023 Lamb YN, Hoy SM.
europepmc +3 more sources